European journal of haematology
-
Randomized Controlled Trial Multicenter Study
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
To evaluate the incremental cost-utility ratio (ICUR) of idelalisib in combination with rituximab (IR) versus rituximab monotherapy (R) in the treatment of patients with relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL), from the Spanish National Health System (NHS) perspective. ⋯ IR can be considered a cost-effective treatment compared to R, in the treatment of R/R CLL patients for the Spanish NHS.